Clinical Trial

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

Study acronym: PREFer
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.
Trial Details
NCT Number NCT06916416
Lead Sponsor University of Cologne
Conditions Classical Hodgkin Lymphoma
Enrollment 50 participants
Start Date 2025-06
Primary Completion 2026-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-04-08